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Addition of chemotherapy to the treatment of non-small-cell lung cancer (NSCLC) resulted in a modest but clear improvement in
the survival of selected patients. To ascertain if this translates to improved survival in the whole population of patients, we conducted
a retrospective population-based study of a sample of 1738 patients diagnosed with primary NSCLC in a French department
between 1982 and 1997. The proportion of women, metastatic cases and adenocarcinoma changed significantly over time, as did
their management: use of chemotherapy alone increased from 9.7 to 28.1% (Po0.0001), while the use of radiotherapy alone
decreased from 32.2 to 9.4% (Po0.0001). The 5-year survival probability was 15.7 % for all patients and 32.6% for those with
resectable disease. The 1- and 2-year survival probabilities were 38.2 and 15.6% in locally advanced disease, and were, respectively,
16.8 and 5.2% in metastatic disease. Disease extent and histological subtype were significant independent prognostic factors. Survival
of resectable disease was longer among patients treated with surgery or surgery plus chemotherapy, while better outcomes for locally
advanced disease were associated with radiation plus chemotherapy. In metastastic disease, patients treated by classical agent without
platin or palliative care only had the shortest survival. Despite changes in treatment in accordance with the state-of-the-art, overall
survival did not improve over time. It is not unlikely that more patients with bad PS were diagnosed during the latter end of the study
period. This could at least partially explain the absence of detection of an overall improvement in survival.
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Lung cancer, one of the most common malignancies, is the leading
cause of cancer death among men through out the industrialised
world (Ferlay et al, 2001). Since 1987, lung cancer has caused more
deaths than breast cancer among North American women (US
Public Health Service, 2001), and it is now the third leading cause
of cancer deaths among French women (Hill and Doyon, 2004).
Non-small-cell lung cancer accounts for approximately 75% of all
lung cancers. Its prognosis is poor: 5-year survival rates range from
60% in resected stage IA disease to 5% in stage IIIB and 1% in stage
IV (Mountain, 1997). At diagnosis, approximately 75% of patients
have tumours classified as stage III or IV disease (Fry et al, 1999).
Management of Non-small-cell lung cancer (NSCLC) has
changed substantially over the past two decades with an increasing
use of chemotherapy. At the beginning of the 1980s, the standard
treatments were surgery for resectable tumours, mediastinal
irradiation for locally advanced disease and supportive care for
metastatic disease. Meta-analyses (Souquet et al, 1993; NSCLCCG,
1995) of the clinical trials comparing chemotherapy vs no
chemotherapy report modest but clear improvement in survival
for patients with metastatic or locally advanced disease who are
treated with cisplatin-based chemotherapy and a trend towards
improved survival with adjuvant chemotherapy in resectable
disease. (The favourable impact of adjuvant chemotherapy has
just been demonstrated very recently; The IALT Collaborative
Group, 2004). Preoperative chemotherapy strategies might im-
prove survival in resectable stage IIIA disease (Roth et al, 1994) as
well as in stages I and II (Depierre et al, 2002).
To evaluate the effect on survival of these management changes
in a population-based study, we conducted a retrospective study
over a 16-year period of a sample of 1738 patients diagnosed with
NSCLC in the department of Bas-Rhin (northeastern France).
PATIENTS AND METHODS
Patients
The Bas-Rhin population-based cancer registry furnished us with a
list of patients with confirmed NSCLC. This department had a
population of roughly 1000000 inhabitants during the study
period (INSEE, 1982, 1990, 1999). We included 40% of the 5071
cases diagnosed between 1982 and 1997 and randomly selected
2028 patients, stratified by year of diagnosis.
We reviewed the medical records of each patient and excluded
those with in situ carcinoma or a combination of small-cell and
NSCLC. The following data were collected: age, sex, date of
diagnosis, histological subtype, investigations performed for
diagnostic and staging purposes and disease extent. We did not
attempt to assign stages retrospectively but used the stage assigned
by the patient’s physician at diagnosis: resectable disease, locally
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sadvanced unresectable disease and metastatic disease. The stage
was classified as undetermined if the chart did not report the local
extent of the disease at diagnosis and if no metastatic site was
detected.
Initial treatment (surgery, radiotherapy, chemotherapy, pallia-
tive care) and any clinical trial participation were also recorded.
Chemotherapy was divided into classical agents and more recent
agents (vinorelbine, gemcitabine, irinotecan) and subdivided into
protocol with or without platin.
Survival was estimated from the date of pathological diagnosis.
The end of follow-up was 31 December 2002.
Statistical methods
Descriptive analysis We defined four consecutive periods cover-
ing 4 years each. Differences between proportions were assessed
with either Pearson’s w
2 test or Fisher’s exact test. Differences
between the means of continuous variables were evaluated with
Student’s t-test or, if the comparison involved more than two
groups, one-way analysis of variance. The 8.2 SAS software
package (SAS Institute, Cary, NC, USA) was used to analyse the
data.
Survival analysis Our study covered 16 years. To eliminate the
effect of improved survival for the other pathologies and the effect
of age-related mortality, we conducted simple and multiple
regressive analysis of relative rather than crude survival (Este `ve
et al, 1990) with the RELSURV software package (He ´delin, 2003).
The variables with a P-value of 0.20 or less in the simple regressive
analysis were entered in the multiple regressive analysis. Sex and
period were forced in the model. The proportionality assumption
has been verified using interaction with time. Interactions between
variables were tested, and none was statistically significant.
Power considerations Our principal objective was to determine
whether relative survival globally changed in NSCLC patients
between 1982 and 1997. Using registry data, we estimated that the
5-year relative survival rate was 15% in the early 1980s, and we
wanted to be able to detect an increase of at least five points, that
is, a 5-year relative survival rate of 20% at the end of the 1990s
under the assumption of the proportionality of the risks. With the
formula given in Jung and Hui (2002) and assuming a one-sided
test with an alpha level of 0.05 and a power of 0.80, we estimated
that a sample size of 490 patients would be required in each of the
four periods.
RESULTS
Descriptive analysis
We excluded 290 of the 2028 patients randomly selected from the
registry: 197 patients had missing medical records, and 93 did not
meet the inclusion criteria. The study thus included 1738 patients,
89.8% of the 1935 eligible.
The 197 eligible patients excluded from the study differed in
some ways from the 1738 patients included. The proportion of
women in these groups was 17.2 and 9.2%, respectively
(P¼0.0001), the median age 69.0 and 63.0 years (Po0.0001),
and their median survival time (MST) substantially different (21.6
vs 45.3 weeks, P¼0.00006). The proportion of cases with missing
data decreased significantly over the study period from 15.5 to
9.5% (P¼0.0109). Table 1 summarises the patients’ characteristics
and their trends over time.
The proportion of metastatic disease increased over the study
period, and the histological distribution changed, especially in the
last period, adenocarcinoma became more frequent and squamous
cell carcinoma less so (Table 1).
Table 2 reports the diagnostic and staging procedures
performed according to the period.
On 31 December 2002, 5.9% of the patients were still alive, 92.8%
had died and 1.3% had been lost to follow-up.
Table 1 Characteristics of the study sample
1982–85 1986–89 1990–93 1994–97
Period No. % No. % No. % No. % P
Sex
a 0.2044
Male 319 91.4 380 89.4 411 87.6 431 87.1
Female 30 8.6 45 10.6 58 12.4 64 12.9
Age (years) 0.0018
p55 82 23.5 101 23.8 93 19.8 108 21.8
56–70 144 41.3 210 49.4 255 54.4 268 54.1
470 123 35.2 114 26.8 121 25.8 119 24.0
Treatment on protocol
a 11 3.2 6 1.4 20 4.3 36 7.3 0.0001
Disease extent 0.0267
Resectable 182 52.1 197 46.4 204 43.5 202 40.8
Locally advanced 52 14.9 70 16.5 96 20.5 94 19.0
Bilateral 7 2.0 13 3.1 6 1.3 12 2.4
Metastastic 92 26.4 126 29.6 149 31.8 174 35.2
Undetermined 16 4.6 19 4.5 14 3.0 13 2.6
Histology 0.0003
Squamous-cell 229 65.6 282 66.4 300 64.0 267 53.9
Adenocarcinoma 69 19.8 92 21.6 100 21.3 148 29.9
Bronchioloalveolar 13 3.7 16 3.8 26 5.5 18 3.6
Large-cell 35 10.0 34 8.0 41 8.7 51 10.3
Mixed 3 0.9 1 0.2 2 0.4 11 2.2
aLinear trend significant.
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sFrom period 1 through period 4, the mean number of metastatic
sites detected increased from 0.36 to 0.57 (P¼0.0057) and the
mean number of extra-thoracic imaging procedures from 1.79 to
2.87 (Po0.0001). These increases were significantly correlated
(r¼0.13, Po0.0001).
In all, 17 cases discovered incidentally at autopsy or who died
before diagnosis were excluded from the following analyses.
Treatments for each stage differed significantly from the first to
the last study period (Po0.0001, Table 3). Data for cases involving
bilateral disease and undetermined stage are not shown. The
percentage of patients treated with mediastinal irradiation alone
decreased over time from 32.2 to 9.4% (Po0.0001) for every stage.
On the other hand, the combined use of chemo- and radiotherapy
increased significantly over time for the locally advanced stage and
the use of chemotherapy alone increased significantly from 9.7 to
28.1%(Po0.0001), especially for metastatic disease. The use of
surgery alone for resectable disease increased over the study
period, while the use of surgery plus radiotherapy did not change.
Of the patients in this group, 73.0% had tumours resected: 64.1%
with pTNM stage I or II, 25.2% stage IIIA and 8.6% stage IIIB or IV
(2.1% unknown).
Chemotherapy used a single agent in 11.7% of the cases, two in
39.5%, three in 17.8% and four or more in 31.0%. Cisplatin was
one of the drugs in 81.4% of the cases. The drugs used changed
significantly over time: use of vindesine, cyclophosphamide and
lomustine decreased significantly after 1986, while use of
vinorelbine, ifosfamide and mitomycin-C increased significantly
from 1986. The principal regimen during the first two periods was
Table 2 Imaging procedures performed during the study period
1982–85 1986–89 1990–93 1994–97
Period No. % No. % No. % No. % P
Fibrescopy 336 96.6 412 97.4 454 97.8 474 96.3 0.4999
Thoracic-CT scan
a 72 20.7 177 42.0 402 86.8 472 96.3 o0.0001
Thoracic NMR
b 10 2.4 12 2.6 11 2.3 0.9501
Abdominal US 321 92.8 376 90.4 425 92.6 425 89.3 0.1973
Adrenal CT scan
a 18 5.2 83 20.0 220 48.1 245 51.6 o0.0001
Abdominal CT scan
a 12 3.5 30 7.2 82 17.9 134 28.1 o0.0001
Brain CT
a 33 9.6 160 38.5 313 67.7 386 80.9 o0.0001
Bone scan
a 171 49.4 175 42.1 212 46.4 275 57.8 o0.0001
Brain scan
a 67 19.4 16 3.9 0 0.0 0 0.0 o0.0001
Brain NMR
a 1 0.3 3 0.7 7 1.5 10 2.1 0.0823
Mediastinoscopy 2 0.6 4 1.0 6 1.3 5 1.0 0.8181
Other 35 10.1 34 8.2 41 9.0 37 7.8 0.6643
aLinear trend significant.
bw2 calculated from 1986. CT: computed tomography; US: ultrasound; NMR: nuclear magnetic resonance imaging.
Table 3 Therapeutic management over time
1982–85 1986–89 1990–93 1994–97
Period No. % No. % No. % No. % P
Resectable disease
Radiotherapy
a 44 24.4 35 17.9 26 12.7 23 11.4 0.0023
Surgery
a 60 33.3 99 50.5 108 52.9 112 55.4 o0.0001
Chemotherapy 2 1.1 2 1.0 5 2.5 6 3.0 0.4290
Surgery+radiotherapy 31 17.2 41 20.9 34 16.7 24 11.9 0.1149
Surgery+chemotherapy 11 6.1 5 2.6 6 2.9 8 4.0 0.2777
Chemotherapy+radiotherapy 13 7.2 1 0.5 2 1.0 8 4.0 0.0004
Surgery+radio+chemotherapy 8 4.4 3 1.5 11 5.4 10 5.0 0.2043
Supportive care 11 6.1 10 5.1 12 5.9 11 5.4 0.9745
Locally advanced disease
Radiotherapy
a 28 53.8 49 70.0 39 40.6 12 12.9 o0.0001
Chemotherapy 7 13.5 3 4.3 12 12.5 11 11.8 0.2720
Chemotherapy+surgery 0 0.0 0 0.0 0 0.0 2 2.2 0.2419
Chemo+radiotherapy
a 11 21.2 9 12.9 29 30.2 55 59.1 o0.0001
Chemo+surgery+radiotherapy 0 0.0 3 4.3 6 6.3 4 4.3 0.3247
Supportive care 6 11.5 6 8.6 10 10.4 9 9.7 0.9552
Metastatic disease
Radiotherapy
a 28 31.1 30 24.6 17 11.5 8 4.6 o0.0001
Chemotherapy
a 24 26.7 32 26.2 64 43.2 113 65.3 o0.0001
Chemotherapy+surgery 0 0.0 1 0.8 1 0.7 2 1.2 0.9155
Chemo+radiotherapy
a 17 18.9 4 3.3 15 10.1 10 5.8 0.0003
Surgery 0 0.0 0 0.0 1 0.7 0 0.0 0.6754
Chemo+radiotherapy+surgery 0 0.0 0 0.0 0 0.0 1 0.6 0.9999
Supportive care 21 23.3 55 45.1 50 33.8 39 22.5 0.0002
aLinear trend significant
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scisplatin-based chemotherapy with vindesine and/or cyclopho-
sphamide and/or lomustine: 89.3% in 1982–85, and 64.7% in
1986–89. The most common regimen in the last two periods was
the combination of cisplatin and vinorelbine: 29.2% in 1990–93,
and 32.5% in 1994–97. Use of combined chemotherapy including
cisplatin, ifosfamide and/or mitomycin-C began in 1990–93 and
increased steeply over the last two periods: 8.4% in 1990–93, and
19.2% in 1994–97. Monotherapy with vinorelbine began in 1986–
89, when it constituted 4.4% of the chemotherapy regimens, vs
15.0% in 1994–97.
Simple regressive analysis of relative survival
Overall survival did not change significantly during the study
period (P¼0.861). Median survival time was 10.3 months during
the first period and 10.2 months during the last. For resectable
disease, however, improvement of survival over time was on the
borderline of statistical significance (P¼0.066): MST in this group
increased from 21.1 months in 1982–85 to 35.8 months in 1990–93
and decreased slightly thereafter to 33.0 months in 1994–97. No
differences from the first study period to the last were observed for
locally advanced or metastatic disease (P¼0.273; P¼0.160), with
MST 8.5 and 9.7 months, respectively, in locally advanced disease,
and 4.6 and 4.4 months in metastatic disease.
Overall, the 1-, 2- and 5-year survival probabilities were,
respectively, 45.9, 29.4 and 15.7%. For patients with resectable
disease they were 71.3, 53.9 and 32.6%, and 79.2, 64.2 and 41.1%
for those whose tumours were resected. The 1- and 2-year survival
probabilities for all patients with locally advanced disease were
38.2 and 15.6%, for those treated by radiotherapy alone, 32.7 and
19.0%, and for those receiving radiotherapy and chemotherapy,
49.3 and 17.6%. These survival probabilities for all patients with
metastatic disease were 16.8 and 5.2%, and for those treated with
chemotherapy alone, 24.1 and 5.9%.
In all, 129 patients (7.5%) died within a month of diagnosis: 91
(70.5%) of them received no specific treatment.
Age (Po10
 5), disease extent (Po10
 5), histological subtype
(Po10
 5), and treatment (Po10
 5) all had a significant influence
on survival. Sex (P¼0.840) and inclusion in a clinical trial
(P¼0.775) did not.
Multiple regressive analysis of relative survival
The multiple regressive analysis considered age, sex, disease
extent, histological subtype, period and treatment in a forward
stepwise procedure.
We first included only the pretherapeutic patients’ and disease’s
characteristics. Age over 70 years, advanced disease and mixed
subtype were less favourable prognostic factors, and the adeno-
carcinoma and bronchioloalveolar carcinoma histological subtypes
more favourable (Table 4).
Then we included, separately for each stage (Tables 5, 6, 7),
characteristics of the patients, disease and treatment (because
treatment depends strongly on stage). We excluded patients with
bilateral disease or undetermined stage. We also excluded
treatments administered to fewer than 20 patients, because there
was not enough information to allow us to estimate the
corresponding coefficient in the model (Table 3).
Age had no prognostic value in the models including treatment
variables. Histology was a prognostic factor only in metastatic
disease (Table 7): survival rate was higher for those with
adenocarcinoma than with squamous-cell carcinoma. In resectable
disease, survival was longer among patients undergoing only
surgery or surgery and chemotherapy (Table 5). In locally
advanced disease, the longest survival was observed with radio-
therapy plus chemotherapy (Table 6).
In metastastic disease, patients treated with chemotherapy
including new agents or classical agent with platin had a higher
Table 4 Multiple regressive survival analysis for pretherapeutic char-
acteristics
Variables Hazard ratio CI P
Sex 0.47526
Male 1
Female 0.938 0.786; 1.120
Age (years) 0.00005
p55 1
56–70 1.047 0.914; 1.199
470 1.376 1.177; 1.610
Histology 0.00243
Squamous-cell 1
Adenocarcinoma 0.844 0.733; 0.971
Bronchioloalveolar 0.645 0.469; 0.886
Large-cell 0.972 0.807; 1.171
Mixed 1.758 1.022; 3.026
Disease extent o10
 5
Resectable disease 1
Locally advanced disease 2.785 2.386; 3.251
Metastatic disease 5.410 4.706; 6.219
Bilateral disease 2.079 1.451; 2.978
Undertermined 6.125 4.559; 8.229
Period 0.46030
1982–85 1
1986–89 0.978 0.831; 1.152
1990–93 0.897 0.764; 1.054
1994–97 0.911 0.777; 1.068
Table 5 Multiple regressive survival analysis for pretherapeutic and
therapeutic variables in resectable disease
Variables Hazard ratio IC P
Sex 0.21884
Male 1
Female 0.811 0.575; 1.142
Age (years) 0.79369
p55 1
56–70 1.025 0.802; 1.310
470 0.936 0.679; 1.291
Histology 0.88776
Squamous-cell 1
Adenocarcinoma 0.952 0.741; 1.221
Bronchioloalveolar 0.913 0.576; 1.449
Large-cell 1.069 0.718; 1.591
Mixed 1.481 0.608; 3.605
Treatments o10
 5
Surgery alone 1
Surgery+radio+chemotherapy 1.656 1.055; 2.598
Chemo+radiotherapy 3.761 2.336; 6.055
Surgery+chemotherapy 0.888 0.497; 1.589
Surgery+radiotherapy 1.944 1.492; 2.533
Radiotherapy alone 3.534 2.640; 4.730
Supportive care alone 5.353 3.637; 7.878
Period 0.49530
1982–85 1
1986–89 1.013 0.778; 1.319
1990–93 0.837 0.635; 1.104
1994–97 0.949 0.724; 1.245
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ssurvival rate than patients treated by classical agent without platin
or palliative care only (Table 7).
DISCUSSION
The sex-ratio decreased significantly over time from 10.6/1 in
1982–85 to 6.7/1 in 1994–1997. Analysis of all French registries
over this period shows the same trend in sex-ratio for lung cancer:
10.1/1 in 1980 and 6.0/1 in 1995 (Remontet et al, 2003). This trend
illustrates the progressive burden of this disease in French women,
related to their increasing regular use of tobacco since the end of
the Sixties (Hill, 1998), more than two decades after women began
smoking regularly in the US (US Public Health Service, 1980). The
sex-ratio there is about 2/1 now, and lung cancer is the leading
cause of cancer death in women (US Public Health Service, 2001).
The median age at diagnosis among the 1738 patients included
in the sample was 63 years, lower than in other European
population-based studies, which have found a median age of
roughly 70 years (Gregor et al, 2001; Koyi et al, 2002; Mahmud
et al, 2003). These series, however, unlike our study, included lung
cancer patients (14–26%) not histologically confirmed, the
confirmation rates declining with age (Koyi et al, 2002; Mahmud
et al, 2003).
The distribution of disease extent also changed significantly
during the study period. The percentage of patients with metastatic
disease increased, as did the number of metastatic sites and the
imaging procedures. This suggests that at least part of the
increased frequency of metastatic disease may be due to stage
migration, a well-known phenomenon (Feinstein et al, 1985).
Cases classified as resectable accounted for 45.2% of the entire
sample, and locally advanced stage for only 18.0%. This high
percentage of resectable disease probably has two primary causes,
the first being the absence of thorax CT scans during the early
periods. Second, mediastinoscopy is not routine in France
(Depierre et al, 2002), so that patients with stage IIIA disease
often undergo surgery.
Disease management changed over the study period, especially
for the locally advanced and metastatic stages. Surgery alone
remained the primary treatment for resectable disease throughout
the period. Combined treatments, such as surgery plus radio-
therapy plus chemotherapy or surgery plus chemotherapy,
remained relatively infrequent, as seen in a 10-year survey in the
US (Fry et al, 1999). The meta-analysis published in 1995
(NSCLCCG, 1995) did not provide clear evidence that chemother-
apy, especially adjuvant chemotherapy, is effective in prolonging
survival in these cases. Similarly, only two small randomised
studies of neoadjuvant chemotherapy were published during the
study period (Rosell et al, 1994). Accordingly, no significant
modification in the use of chemotherapy for resectable disease was
to be expected.
Use of radiotherapy alone in resectable disease decreased during
the study period, while surgery was increasingly used. This
observation is consistent with other reports (Janssen-Heijnen
and Coebergh, 2003). This trend may be related to advances in
operative technique and perioperative care that have prompted
greater recourse to surgery (Bolliger and Perruchoud, 1998).
Postoperative radiotherapy in resected stage IIIAN2 disease is
widely used in France as elsewhere (Emami and Perez, 1992) and
did not change significantly during the study period.
The PORT meta-analysis confirmed the detrimental effect of
postoperative radiotherapy in resected stage I and II disease and
found its role in completely resected stage IIIA disease still unclear:
an improvement of the local control but no effect on survival
(PORT Meta-analysis Trialists Group, 1998).
The use of platinum-based chemotherapy in conjunction with
radiotherapy in patients with locally advanced unresectable
Table 6 Multiple regressive survival analysis for pretherapeutic and
therapeutic variables in locally advanced disease
Variables Hazard ratio IC P
Sex 0.07994
Male 1
Female 1.538 0.972; 2.435
Age (years) 0.60239
p55 1
56–70 1.155 0.845; 1.579
470 1.035 0.705; 1.519
Histology 0.68538
Squamous-cell 1
Adenocarcinoma 1.147 0.802; 1.641
Large-cell 0.975 0.635; 1.498
Mixed 2.301 0.516; 10.267
Treatment 0.00009
Chemo+radiotherapy 1
Chemotherapy alone 2.227 1.448; 3.426
Radiotherapy alone 1.457 1.034; 2.053
Supportive care alone 3.560 2.238; 5.665
Period 0.59819
1982–85 1
1986–89 0.796 0.536; 1.183
1990–93 0.974 0.678; 1.399
1994–97 1.002 0.675; 1.487
Table 7 Multiple regressive survival analysis for pretherapeutic and
therapeutic variables in metastatic disease
Variables Hazard ratio IC P
Sex 0.38535
Male 1
Female 0.895 0.696; 1.152
Age (years) 0.63040
p55 1
56–70 0.908 0.725; 1.136
470 0.979 0.745; 1.287
Histology 0.01699
Squamous-cell 1
Adenocarcinoma 0.751 0.607; 0.929
Bronchioloalveolar 0.586 0.351; 0.978
Large-cell 1.023 0.788; 1.330
Mixed 1.361 0.553; 3.347
Treatments o10
 5
Chemotherapy alone with classical
agents and platin
1
Chemotherapy alone with recent
agents and platin
0.749 0.547; 1.026
Chemotherapy alone with recent
agents w/o platin
1.069 0.722; 1.583
Chemotherapy alone with classical
agents w/o platin
2.010 1.142; 3.540
Chemo+radiotherapy 0.727 0.501; 1.055
Radiotherapy alone 1.359 0.982; 1.881
Supportive care alone 2.316 1.749; 3.067
Period 0.23791
1982–85 1
1986–89 0.981 0.732; 1.315
1990–93 1.088 0.821; 1.442
1994–97 1.272 0.949; 1.704
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sNSCLC has become standard in France since the publication by Le
Chevalier et al (1991). In our study, chemotherapy plus radio-
therapy in locally advanced disease increased significantly during
the study period, from 21.2 to 59.1%. Inversely the use of
radiotherapy alone decreased significantly, from 53.8 to 12.9%.
Similar trends in the treatment of locally advanced NSCLC have
been reported for the US (Fry et al, 1999).
The use of chemotherapy for metastatic disease also increased
over time. Practices in our study were consistent with findings in
the meta-analysis (NSCLCCG, 1995) with cisplatin-based
chemotherapy being the most common first-line approach. Many
studies reported that cisplatin-based combinations were associated
with better response rates and sometimes better survival than
monotherapy, and these combinations eventually became standard
practice (Depierre et al, 1994; Le Chevalier et al, 1994). In our
study, 11.7% of the patients treated by chemotherapy received one
drug, 39.5% two, 17.8% three, and 31.0% four or more.
We did not see any improvement in overall survival between
1982 and 1997. In the retrospective analysis of patients with
extensive NSCLC treated in the clinical trials of the SWOG between
1974 and 1988, an improved survival was observed for those
treated with cisplatin-based chemotherapy (Albain et al, 1991), a
treatment introduced during the 1980s. The European retro-
spective analysis of patients with advanced NSCLC enrolled in
clinical trials between 1980 and 1991 observed no improvement in
survival according to period of diagnosis (Paesmans et al, 1995). A
study of 22 years of phase III trials for patients with advanced
NSCLC (Breathnach et al, 2001) showed modest progress in survival
for these patients: MST increased from 5.2 months in the early
period (1973 to 1983) to 5.8 months in the later one (1984 to 1994).
Nevertheless, this improved survival from one clinical trial to
another cannot be definitely attributed to improvement of
therapies. The increasingly restrictive inclusion criteria may be a
factor in the improved outcome of study subjects. These selection
biases limit, of course, the generalisability of the results obtained
in clinical trials to the real-life population of patients. Comorbid-
ities, often linked to tobacco use, may prevent patients in the
general population from receiving the optimal treatment (Janssen-
Heijnen et al, 1998). The Will Rogers phenomenon (Feinstein et al,
1985) may also account for at least some of the improved survival
observed in consecutive trials.
Lead time bias is another possible explanation for the
improvements in survival observed in clinical trials. This bias is
the only one of those mentioned here that is also possible in
population-based studies, because the general population may also
become more aware of lung cancer symptoms over time and
consult earlier. Population-based studies are therefore of the
utmost importance in assessing treatment efficiency and providing
insight into public health policies.
Few population-based analyses of survival in patients with
NSCLC have been published. MST of all patients with NSCLC in
the SEER-database increased from 9.1 months in 1974–75 to 10
months in 1993–94 and the 3- and 5-year survival rates increased,
respectively, by 2 and 4 points (Breathnach et al, 2001). A large
hospital-based cancer registry showed no improvement in survival
from 1985 through 1995 (Fry et al, 1999).
Elderly patients are excluded from clinical trials frequently and
receive optimal treatment less often than younger patients (Earle
et al, 2002). Their frequent comorbidities and frailty often preclude
administration of the standard treatment (Janssen-Heijnen et al,
1998). But advanced age in itself does not contraindicate aggressive
treatment (Deppermann, 2001; Langer et al, 2002). Age was not a
prognostic factor in our study when we took into account the
specific treatment administered. In various cancers, such as
NSCLC (Foucher et al, 1993), studies using relative survival often
dismiss age as a significant prognostic factor.
Performance status is probably the best single prognostic factor
with stage in NSCLC (Albain et al, 1991). Unfortunately, in this
population-based study there were too many missing values. It is
not unlikely that more patients with bad PS were histologically
diagnosed with lung cancer during the latter end rather than at the
beginning of the study period as was demonstrated by UK cancer
registries (Cartman et al, 2002). This could at least partially explain
the absence of detection of an overall improvement in survival.
We did not observe any protective effect linked to female sex in
our study. Several studies report better prognosis for women with
NSCLC cancer than for men (Albain et al, 1991; Paesmans et al,
1995; Radzikowska et al, 2002), although not consistently (Keller
et al, 2002).
Adenocarcinoma was associated with longer survival in the
metastatic stage than squamous-cell carcinoma. The prognostic
role of histological type remains controversial (Sculier et al, 1994;
Charloux et al, 1997; Fry et al, 1999). Changes in pathology
classifications over the years may account in part for these
discrepancies.
Disease stage at diagnosis is the most important prognostic
factor. Five-year relative survival for patients with resectable
disease was 32.6%, regardless of the treatment. It was 41.1% for
those who underwent surgery (alone or combined with other
treatments), which can be compared to the 5-year crude survival in
surgical series: 40.4% for the surgery arm, with or without
postoperative radiotherapy in the IALT trial (The IALT Colla-
borative Group, 2004), and 43% in the surgery alone arm of the
post-operative radiation therapy trial (Dautzenberg et al, 1999).
In our study, among patients with resectable disease, survival
was shorter for those who could not undergo surgery and for those
who had surgery and radiotherapy. This combined therapy,
however, reflects their advanced pTNM stage: 64.6% of them had
post-operative stage IIIA and 11.5% stage IIIB.
In locally advanced disease, the 1-year survival rate was 32.7% for
patients treated by radiotherapy alone and 49.3% for those treated
with radiotherapy plus chemotherapy. These results are similar to
those previously reported in a clinical trial (Le Chevalier et al, 1991).
In metastatic disease, the 1-year survival rate was 16.8% for the
overall sample, it was 24.1% for the patients who received only
chemotherapy, a rate very close to that reported in the
chemotherapy arms of clinical trials comparing chemotherapy to
the best supportive care (NSCLCCG, 1995). Those patients with
metastatic disease who were treated with platin-based chemother-
apy had the best survival and in this group we observed a trend
towards better results with the new agents combined with platin.
The recently published phase III trials that included hundreds of
patients with advanced NSCLC, did not demonstrate the super-
iority of any one combination of a platinum salt with a new agent
over any other (Kelly et al, 2001; Schiller et al, 2002).
Overall, 16.7% of our patients received only palliative care. This
percentage is to be compared to the 14% to 19% in the NCDB
series (Fry et al, 1999), 43.2% in the Scottish population-based
series (Gregor et al, 2001), and 39.8% in the Irish (Mahmud et al,
2003). The higher percentages in the two latter studies may be
partly explained by the inclusion of patients with unconfirmed lung
cancer and probably too frail to undergo diagnostic procedures.
Despite changes in treatments in accordance with the state of the
art, survival did not improve. Nevertheless, the survival rates
observed in our series are very similar to those reported in recent
phase III clinical trials that include highly selected patients.
Several authors argue that SCLC is a more chemoresponsive
disease than NSCLC, so that improved survival is more likely to be
observed in patients with the former disease (Breathnach et al,
2001; Janssen-Heijnen and Coebergh, 2003). A previous study
observed a significant improvement in survival in patients
diagnosed with SCLC in the Bas-Rhin between 1981–83 and
1993–94 (Lebitasy et al, 2001).
These findings may also reflect the continuing pre-eminence of
surgery in curing NSCLC. The benefits of chemotherapy in more
advanced disease still appear too small to be translated into
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simproved overall survival in an entire patient population, some
being unable to receive chemotherapy. Thus, the impact of
these newer treatments on survival will become apparent when a
much greater proportion of patients will be treated with the
appropriate treatment, and perhaps the final cohort was too early
in the evolution of NSCLC management to outbalance the above
factors.
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